Alvant is a British advanced materials technology group that specialises in the design, development, testing and manufacture of Aluminium Metal Matrix Composite materials and components (AMCs). These components are demanded the engineering applications across a wide range of industry sectors. Till now, they have invested £10 million for the development, prototyping & testing AMC materials with several projects secured with distinguished clients such as Ford & Safran. Alvant has seen new advances in current customer projects and applications. Space - Tesla, Design for Demise(D4D), Bauer Hockey are some examples. With the proceeds, the company will accelerate commercialisation and growth at the rate its customers are presently demanding.
days to go:
Expired
investment:
Withheld
A purpose-focused digital nutrition brand with a goal to enhance amino acids' impact worldwide, aiming to transform human health and performance; Having sold over 10,000 units to customers across 30+ countries, generating a monthly revenue of £27,000; Successfully raised £270,000 in funding, achieving overfunding with EIS approval and activating a £300,000 growth loan through FSE Group, further supported by the founder's personal guarantee of £150,000 due to strong confidence in success.
Experience the next level of amino acid products with a delightful twist - No more struggling with water binding and bitterness. Through innovative methods, we've introduced the market's first enjoyable amino acid drink.
days to go:
Expired
investment:
£275,000
Antev Limited (Antev) is a clinical-stage biopharmaceutical firm which focuses on the evolution of a drug used for prostate cancer, Teverelix TFA. The company is working on growing its copyright protection and is currently developing phase IIb clinical plans for prostate cancer. Antev is a pre-revenue company that aims at increasing its shareholder value by progressing the development of teverelix TFA towards registration whose approval is anticipated from 2023 onwards. The proceeds will be used for production, IP development, working capital and to develop a phase IIb repeat dosing clinical trial in prostate cancer.
days to go:
Expired
investment:
Withheld
Metal matrix composite components and materials, primarily comprised of aluminium for use in the engineering and manufacturing industries. Alvant specialise in designing, developing and producing the composite for well-known clients such as Ford and Safran.
In the last financial year, Alvant achieved a turnover of almost £617k and has invested more than £10m towards manufacturing and testing their own product. Alvant is now raising funds to distribute their components to a wider market and expand the number of commercial applications that would benefit from their materials.
days to go:
Expired
investment:
£2,105,001
Based in Kent, Folc is an English Rosé wine producer. They distribute through their website, wholesale and trade stocklists including in the first-class cabin on Virgin Atlantic. Sourced from family-run growers, the company has won multiple awards including IEWA Gold and the prestigious Star of Kent.
With over 18,000 bottles sold, all packaging is 100% recycled or recyclable with the bottles made from 94% recycled glass.
days to go:
Expired
investment:
£260,000
Go In Store is a first person shopping experience that allows online visitors to experience a store as if they were in the store. Customers can engage with a retail associates in real time. They intend on using new technologies to bring this human to human virtual shopping experience to life.
days to go:
Expired
investment:
£275,852
GreenPiP produce sustainably sourced, green packaging for the packaging market. Their packaging will be made of just one material and therefore it is easier for the agencies that deal with recycling once it has been discarded.
days to go:
Expired
investment:
£105,000
Hemspan states that it designs bio-based building systems and products for construction by combining modern methods, technology and hemp to produce net-zero carbon solutions. The company argues that every time an average house is built, the CO2 emitted by the manufacture, transport and assembly of the materials used is around 50 to 60 tonnes. Hemspan says that one hectare of UK-grown industrial hemp can absorb 11 tonnes of CO2 each year with regeneratively farmed hemp capable of sequestering a further 6 tonnes per hectare of CO2 into the soil each year. Hemspan intends to activate significant demand for hemp farming in the UK and develop processing technologies to reduce reliance on imports and enable large scale manufacturing of bio-based cladding and insulation products that spin out of R&D programmes. It asserts that the global industrial hemp market is expected to grow at 25% CAGR reaching US$ 27 billion by 2028. It aims to be a contender in this segment.
days to go:
Expired
investment:
£200,000
Lightpoint Medical is a technology company that is a pioneer in developing and marketing precision-guided cancer surgery. Surgeons aren't able to see if the cancerous tissue has been removed in its entirety or not during a surgery. To better this situation, the company has developed an imaging technology based on PET radiopharmaceuticals, more precisely, Cerenkov Luminescence Imaging (CLI), which helps surgeons to detect cancer in a real-time during surgery. The company's first product has received marketing authorisation, i.e., the CE (European Conformity) Mark. A second product, a laparoscopic device for prostate cancer is in development. A non-clinical device has also been released. For its efforts, Lightpoint Medical won the 'Best in Show' Award at the 2014 MedTech Investing Europe Conference. The company aims to utilise the investment to scale its business.
days to go:
Expired
investment:
Withheld
A medical condition management platform allowing clinicians to create their own app to improve a patient's health whilst reducing costs. Living With develops smart apps specific to a person's condition, they currently have 3 products with another in the development stage. Their primary app, Squeezy, is the top paid medical app in the UK that helps patients with their pelvic floor exercises. Other apps, allow clinicians to monitor a patient's bowel and bladder health, as well as those with rheumatoid arthritis. These apps are already in use at multiple NHS Trusts and clinics.
Funds are being raised to complete development of their apps to help those with lupus and lung cancer, in addition to further developing their existing products. The company aims to have thousands of apps that will be available worldwide to provide self-service treatment at any time. Living With is expecting to earn £1.07m in revenue by the end of March 2019.
days to go:
Expired
investment:
£250,000
